Vilon
Aliases: Lys-Glu · KE dipeptid
Last verified: 2026-09-23
The short version
A dipeptide (Lys-Glu) from the thymic series — immunomodulator and geroprotector in preclinical models; one of the smallest active "peptide bioregulators". Key fact: Human data are limited: small trials or case-series reports exist, without large randomized studies. Preclinical aging/immunity studies (Russian literature). Status: research chemical. Not approved as a drug; supplement/research.
Identity & type
- Molecular type
- bioregulator
- Origin
- A dipeptide (Lys-Glu) from the thymic series — immunomodulator and geroprotector in preclinical models; one of the smallest active "peptide bioregulators".
Mechanism of action
Gene-expression regulation (DNA/histone interaction per the Khavinson model), immunomodulation.
not confirmed in humans
Dosing & routes
Official / clinical context
No approved official document exists for Vilon. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
1–5 mg/day SC/IM in courses. A dipeptide (Lys-Glu): in Russian studies immunostimulation and regeneration; expected effects are subtle, mostly in the elderly.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
A dipeptide (Lys-Glu): in Russian studies immunostimulation and regeneration; expected effects are subtle, mostly in the elderly.
Protocol — official vs community
Official / label
No approved protocol exists. Vilon is a research peptide bioregulator (Lys-Glu dipeptide) with no registered drug product in any major market.
Duration: —
Human data are limited to small Russian series; the gene-regulatory mechanism is the standard Khavinson-school model.
Community (anecdotal)
1–5 mg SC or IM daily for 10–20 days.
- Cycle:
- 1–2 courses per year.
- Break:
- Months between courses — built into the model.
The regimen is the shared Khavinson bioregulator course pattern; only the organ-targeting claim (thymus/immunity, anti-aging) differs from the rest of the series.
Human evidence
Human data are limited: small trials or case-series reports exist, without large randomized studies. Preclinical aging/immunity studies (Russian literature).
Preclinical evidence
Preclinical aging/immunity studies (Russian literature).
Known risks
- No significant ones reported.characterized
- Unregulated injectable supply — sterility, purity and accurate dose not assuredtheoretical
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term human safety
- Optimal dose and pharmacokinetics
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.